Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elimusertib in Pediatric Patients With Relapsed or Refractory Solid Tumors
NCT05071209Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of elimusertib in solid tumor, Ewing sarcoma, alveolar rhabdomyosarcoma (ARMS), lymphoma, sponsored by National Cancer Institute. Started Dec 2021; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
solid tumorEwing sarcomaalveolar rhabdomyosarcoma (ARMS)lymphoma
Beyond the preview
Go deeper on NCT05071209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071209.